Independent clinical research in Europe

Lancet

Volumn 364, Issue 9446, 2004, Pages 1723-1726

  Remuzzi, Giuseppe ^a,d   Schieppati, Arrigo ^a   Boissel, Jean Pierre ^b   Garattini, Silvio ^a   Horton, Richard ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITÉ LYON 1   (France)

^c THE LANCET   (United Kingdom)

^d MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; HORMONE; NEW DRUG; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT;

CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EUROPE; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; MENOPAUSAL SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW;

EID: 7644228634     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17360-1     Document Type: Note

References (32)

1. Bell J. Resuscitating clinical research in the United Kingdom. BMJ. 327:2003;1041-1043
2. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 290:2003;1624-1632
3. Murray CJL, Feachem RGA, Phillips MA, Willis C. Adult morbidity: limited data and methodologic uncertainty. Feachem RG, Kjellstrom T, Murray CJ, Over M, Phillips MA. The health of adults in the developing world. 1992;113-160 Oxford University Press, New York
4. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet. 357:2001;1851-1853
5. Cornu C, Cano A, Pornel B, Melis GB, Boissel JP. Could institutional clinical trials exist in Europe? EUTERP Pilot Study Group. European Trial of Estrogen/progestin Replacement treatment in Post-menopause. Lancet. 353:1999;63-64
6. Henry D, Lexchin J. The pharmaceutical industry as a medicines provider. Lancet. 360:2002;1590-1595
7. Arlington S. Pharma2005: an industrial revolution in R&D. New York, NY: PriceWaterhouseCoopers; 1998. http://www.pwcglobal.com/extweb/indissue.nsf/ DocID/CA1B47532AE8171780256A8C0037B9F2 (accessed May, 2002).
8. Changing patterns of pharmaceutical innovation. A research report by The National Institute for Health Care Management. Washington DC, May 2002. Available at http://www.nihcm.org/innovations.pdf (accessed December, 2003).
9. Editorial. Facing our demons. Nat Rev Drug Discov 2003; 2: 87.
10. Infectious Disease Society of America. Defining the Antimicrobial Availability Problem. http://www.idsociety.org/Template.cfm?Section= Home&CONTENTID=7455&TEMPLATE=/ContentManagement/ContentDisplay.cfm (accessed August, 2004).
11. Weinstein MC. The cost-effectiveness of orphan drugs. Am J Public Health. 81:1991;414-415
12. Schieppati A, Garattini S, Remuzzi G. Modulating the profit motive to meet needs of the less-developed world. Lancet. 358:2001;1638-1641
13. Trouiller P, Torreele E, Olliaro P, et al. Drugs for neglected diseases: a failure of the market and a public health failure? Trop Med Int Health. 6:2001;945-951
14. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet. 355:2000;2037-2040
15. Centers for Medicare and Medicaid Coverage. Air-fluidized beds for pressure ulcers. http://www.cms.hhs.gov/coverage/download/id4.pdf (accessed August, 2002).
16. National Institutes of Health, Grants-OER Home Page. Minimally invasive surgical therapies treatment consortium for benign prostatic hyperplasia. Available at: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-01-024.html (accessed July 5, 2002).
17. Bodenheimer T. Uneasy alliance. Clinical investigators and the pharmaceutical industry. N Engl J Med. 342:2000;1539-1544
18. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 326:2003;1171-1173
19. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 326:2003;1167-1170
20. Garattini S, Bertele V. Adjusting Europe's drug regulation to public health needs. Lancet. 358:2001;64-67
21. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA. 282:1999;786-790
22. Perucca E. What can we learn from clinical trials of anticonvulsant drugs in epilepsy? Eur J Pain. 6:(suppl A):2002;35-44
23. Angell M. Is academic medicine for sale? N Engl J Med. 342:2000;1516-1518
24. Choudhry NK, Stelfox HT, Detsky AS. Relationship between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 287:2002;612-617
25. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. Lancet. 358:2001;854-856
26. Anon. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of good clinical trials on medicinal products for human use. Official J Eur Communities 2001; L121: 34-44.
27. Meunier F, Lacombe D. European Organisation for Research and Treatment of Cancer's point of view. Lancet. 362:2003;663-664
28. Meldolesi A. EU directive on clinical trials penalizes small sponsors. Nat Biotechnol. 21:2003;838
29. Anon. Editorial. Who's afraid of the European Clinical Trials Directive? Lancet 2003; 361: 2167.
30. Chalmers I, Rounding C, Lock K. Descriptive survey of non-commercial randomised controlled trial in the United Kingdom, 1980-2002. BMJ. 327:2003;1017-1020
31. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 288:2002;2981-2997
32. Bassand JP, Martin J, Ryden L, Simoons M. European Society of Cardiology. The need for resources for clinical research: the European Society of Cardiology calls for European, international collaboration. Lancet. 360:2002;1866-1869